A short time later, further metabolites were isolated from
the same fungus and named stagonolides B-I.3 They also
showed phytotoxic activity against C. arVense, although
except for stagonolide H, the activity was much weaker than
that of stagonolide A. Most particularly, stagonolide G was
essentially inactive. Figure 1 shows the structures of three
of the stagonolides.
Scheme 1. Retrosynthetic Analysis of Structure 1
The similarity of their structures with those of other
bioactive 10-membered lactones of natural origin (see
Figure 1)4 has attracted the attention of several groups,
who have devised stereoselective syntheses for lactones
of this type. As a matter of fact, stagonolides A,5 B,5b,6
C,7 F,8 and G9 have succumbed to total synthesis in the last
2 years.
Homoallyl alcohol 2 was prepared as reported12 by means
of asymmetric Brown allylation of a silylated 4-hydroxy-butanal
(Scheme 1, C with P3 ) TPS). Protection of the hydroxyl group
as its MOM derivative13 was followed by desilylation with
TBAF to yield primary alcohol 4.14 All attempts at direct
oxidation of 4 to acid 6 failed. However, PCC oxidation of
alcohol 4 to aldehyde 5 followed by sodium chlorite oxidation15
gave 6 in a fair overall yield (Scheme 2).
In recent years, we have been involved in the total synthesis
of several medium- and large-ring lactones.10 In the present
paper, we are disclosing our own synthesis of compound 1,
which has the structure proposed for stagonolide G. The
retrosynthetic concept followed is presented in Scheme 1.
Retrosynthetic cleavage of the lactone C-O bond and the
olefinic CdC bond (via ring-closing metathesis, RCM) in 1
leads to fragments A and B. Acid A can be referred via
inverse allylation and functional group interchange to the
protected 4-hydroxybutanal C. The monoprotected diol B
should be amenable to preparation by means of an asym-
metric R-alkoxyallylation11 of acetaldehyde with the chiral
(Z)-γ-alkoxyallylborane D.
Scheme 2
.
Synthesis of Acid 6 (≡ A, P1 ) MOM)a
(2) Berestetskiy, A.; Dmitriev, A.; Mitina, G.; Lisker, I.; Andolfi, A.;
Evidente, A. Phytochemistry 2008, 69, 953–960.
(3) (a) Evidente, A.; Cimmino, A.; Berestetskiy, A.; Mitina, G.; Andolfi,
A.; Motta, A. J. Nat. Prod. 2008, 71, 31–34. (b) Evidente, A.; Cimmino,
A.; Berestetskiy, A.; Andolfi, A.; Motta, A. J. Nat. Prod. 2008, 71, 1897–
1901.
(4) For reviews on various synthetic, biosynthetic, or pharmacological
aspects of medium-ring (8-11 membered) lactones, see: (a) Dra¨ger, G.;
Kirschning, A.; Thiericke, R.; Zerlin, M. Nat. Prod. Rep. 1996, 13, 365–
375. (b) Shiina, I. Chem. ReV. 2007, 107, 239–273. (c) Ferraz, H. M. C.;
Bombonato, F. I.; Longo, L. S., Jr. Synthesis 2007, 3261–3285. (d) Ferraz,
H. M. C.; Bombonato, F. I.; Sano, M. K.; Longo, L. S., Jr. Quim. NoVa
2008, 31, 885–900. (e) Ishigami, K. Biosci. Biotechnol. Biochem. 2009,
73, 971–979.
a Acronyms and abbreviations: TPS, tert-butyldiphenylsilyl; MOM
methoxymethyl; TBAF, tetra-n-butylammonium fluoride hydrate; PCC,
pyridinium chlorochromate; DIPEA, N,N-diisopropylethylamine.
(5) (a) Srihari, P.; Kumaraswamy, B.; Rao, G. M.; Yadav, J. S.
Tetrahedron: Asymmetry 2010, 21, 106–111. (b) Prabhakar, P.; Rajaram,
S.; Reddy, D. K.; Shekar, V.; Venkateswarlu, Y. Tetrahedron: Asymmetry
2010, 21, 216–221. (c) Mohapatra, D. K.; Somaiah, R.; Rao, M. M.; Caijo,
F.; Mauduit, M.; Yadav, J. S. Synlett 2010, 1223–1226. (d) Srihari, P.; Rao,
G. M.; Rao, R. S.; Yadav, J. S. Synthesis 2010, 2407–2412.
(6) (a) Srihari, P.; Kumaraswamy, B.; Somaiah, R.; Yadav, J. S. Synthesis
2010, 1039–1045. (b) Giri, A. G.; Mondal, M. A.; Puranik, V. G.; Ramana,
C. V. Org. Biomol. Chem. 2010, 8, 398–406.
In the only other, very recently published synthesis of
stagonolide G,9 a fragment equivalent to B (P2 ) Bn) was
prepared through a nine-step sequence from D-glucose
diacetonide. In the present synthesis, a shorter and more
efficient sequence has been utilized (Scheme 3). Our first
idea was to lithiate the MOM derivative of allyl alcohol and
then treat the organolithium thus formed with B-methoxy-
diisopinocampheylborane (Ipc2BOMe). The resulting chiral
(7) (a) Mohapatra, D. K.; Dash, U.; Naidu, P. R.; Yadav, J. S. Synlett
2009, 2129–2132. (b) Jana, N.; Mahapatra, T.; Nanda, S. Tetrahedron:
Asymmetry 2009, 20, 2622–2628.
(8) Perepogu, A. K.; Raman, D.; Murty, U. S. N.; Rao, V. J. Bioorg.
Chem. 2009, 37, 46–51.
(9) Srihari, P.; Kumaraswamy, B.; Bhunia, D. C.; Yadav, J. S.
Tetrahedron Lett. 2010, 51, 2903–2905.
(10) (a) Murga, J.; Falomir, E.; Garc´ıa-Fortanet, J.; Carda, M.; Marco,
J. A. Org. Lett. 2002, 4, 3447–3449. (b) Garc´ıa-Fortanet, J.; Murga, J.;
Falomir, E.; Carda, M.; Marco, J. A. J. Org. Chem. 2005, 70, 9822–9827.
(c) Garc´ıa-Fortanet, J.; Carda, M.; Marco, J. A. Tetrahedron 2007, 63,
12131–12137. (d) D´ıaz-Oltra, S.; Angulo-Pacho´n, C. A.; Kneeteman, M. N.;
Murga, J.; Carda, M.; Marco, J. A. Tetrahedron Lett. 2009, 50, 3783–3785.
(e) D´ıaz-Oltra, S.; Angulo-Pacho´n, C. A.; Murga, J.; Carda, M.; Marco,
J. A. J. Org. Chem. 2010, 75, 1775–1778. (f) D´ıaz-Oltra, S.; Angulo-Pacho´n,
C. A.; Murga, J.; Falomir, E.; Carda, M.; Marco, J. A. Chem.-Eur. J., in
press.
(12) Brimble, M. A.; Bryant, C. J. Org. Biomol. Chem. 2007, 5, 2858–
2866. In our hands, 2 was obtained with an enantiomeric purity above 99%
(see the Supporting Information).
(13) Wuts, P. G. M.; Greene, T. W. Greene’s ProtectiVe Groups in
Organic Synthesis; 4th ed.; John Wiley and Sons: New York, 2007; pp
30-38.
(14) Compound 4 has previously been prepared with a lower optical
purity (84%) alongside a different reaction sequence: Takahata, H.; Kubota,
M.; Momose, T. Tetrahedron: Asymmetry 1997, 8, 2801–2810.
(15) The reaction conditions for this oxidation were taken from
ref 6b.
(11) For a review of this specific allylation type, see: Lombardo, M.;
Trombini, C. Chem. ReV. 2007, 107, 3843–3879.
Org. Lett., Vol. 12, No. 24, 2010
5753